Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jun 7, 2007; 13(21): 2967-2972
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967
OAC7 (n = 69) | OAC14 (n = 62) | |
Age (yr) | 47.5 ± 16 | 45 ± 15 |
Male | 27 (39.1) | 18 (29) |
Smokers | 14 (20.3) | 21 (33.9) |
Previous antibiotic exposure | ||
Betalactamics | 56 (81.2) | 51 (82.3) |
Clarithromycin | 13 (18.8) | 18 (29) |
Metronidazol | 13 (18.8) | 12 (19.4) |
Tetracyclines | 32 (46.4) | 26 (41.9) |
Endoscopic diagnosis | ||
Ulcer disease | 14 (20.3) | 24 (38.7) |
Non-ulcer disease | 44 (63.8) | 30 (48.4) |
Normal | 11 (15.9) | 8 (12.9) |
-
Citation: Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, Arellano M, Medina B, Pattillo A, Greig D, Arrese M, Rollan A. Optimal length of triple therapy for
H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007; 13(21): 2967-2972 - URL: https://www.wjgnet.com/1007-9327/full/v13/i21/2967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i21.2967